102 related articles for article (PubMed ID: 16143544)
1. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A.
Sharma S; Zhou Y; Singh BR
Protein Expr Purif; 2006 Feb; 45(2):288-95. PubMed ID: 16143544
[TBL] [Abstract][Full Text] [Related]
2. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
Zhou Y; Singh BR
Protein Expr Purif; 2004 Mar; 34(1):8-16. PubMed ID: 14766296
[TBL] [Abstract][Full Text] [Related]
3. Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain.
Chen R; Shi J; Cai K; Tu W; Hou X; Liu H; Xiao L; Wang Q; Tang Y; Wang H
Protein Expr Purif; 2010 May; 71(1):79-84. PubMed ID: 19932180
[TBL] [Abstract][Full Text] [Related]
4. Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.
Mansour AA; Mousavi SL; Rasooli I; Nazarian S; Amani J; Farhadi N
Biologicals; 2010 Mar; 38(2):260-4. PubMed ID: 19879159
[TBL] [Abstract][Full Text] [Related]
5. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
Baldwin MR; Bradshaw M; Johnson EA; Barbieri JT
Protein Expr Purif; 2004 Sep; 37(1):187-95. PubMed ID: 15294297
[TBL] [Abstract][Full Text] [Related]
6. Recombinant expression and purification of the botulinum neurotoxin type A translocation domain.
Lacy DB; Stevens RC
Protein Expr Purif; 1997 Nov; 11(2):195-200. PubMed ID: 9367816
[TBL] [Abstract][Full Text] [Related]
7. High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain.
Li L; Singh BR
Protein Expr Purif; 1999 Dec; 17(3):339-44. PubMed ID: 10600450
[TBL] [Abstract][Full Text] [Related]
8. Characterization of LC-HCC fusion protein of botulinum neurotoxin type A.
Singh MK; Dhaked RK; Singh P; Gupta P; Singh L
Protein Pept Lett; 2011 Mar; 18(3):295-304. PubMed ID: 21054265
[TBL] [Abstract][Full Text] [Related]
9. Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A.
Yu YZ; Ma Y; Chen YX; Gong ZW; Wang S; Yu WY; Sun ZW
Hum Vaccin; 2011 Oct; 7(10):1090-5. PubMed ID: 21941093
[TBL] [Abstract][Full Text] [Related]
10. Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neurotoxin type A.
Kadkhodayan S; Knapp MS; Schmidt JJ; Fabes SE; Rupp B; Balhorn R
Protein Expr Purif; 2000 Jun; 19(1):125-30. PubMed ID: 10833399
[TBL] [Abstract][Full Text] [Related]
11. Optimization of the BoNT/A-Hc expression in recombinant Escherichia coli using the Taguchi statistical method.
Yari K; Fatemi SS; Tavallaei M
Biotechnol Appl Biochem; 2010 May; 56(1):35-42. PubMed ID: 20412050
[TBL] [Abstract][Full Text] [Related]
12. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate.
Fu Z; Chen S; Baldwin MR; Boldt GE; Crawford A; Janda KD; Barbieri JT; Kim JJ
Biochemistry; 2006 Jul; 45(29):8903-11. PubMed ID: 16846233
[TBL] [Abstract][Full Text] [Related]
13. High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.
Dhaliwal HK; Thiruvanakarasu N; Kumar R; Patel K; Ambrin G; Cai S; Singh BR
Protein J; 2017 Dec; 36(6):489-501. PubMed ID: 29030733
[TBL] [Abstract][Full Text] [Related]
14. Peptide inhibitors of botulinum neurotoxin by mRNA display.
Yiadom KP; Muhie S; Yang DC
Biochem Biophys Res Commun; 2005 Oct; 335(4):1247-53. PubMed ID: 16122707
[TBL] [Abstract][Full Text] [Related]
15. [Effective expression of fragments of a botulinum neurotoxin type A gene, coding for the L-chain and H-chain in E. coli, with formation of products causing protective immunity to administration of the toxin].
Vertiev IuV; Zdanovskiĭ AG; Borinskaia SA; Martin T; Gening EL; Iankovskiĭ NK
Mol Gen Mikrobiol Virusol; 2000; (4):3-7. PubMed ID: 11186457
[TBL] [Abstract][Full Text] [Related]
16. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.
Tavallaie M; Chenal A; Gillet D; Pereira Y; Manich M; Gibert M; Raffestin S; Popoff MR; Marvaud JC
FEBS Lett; 2004 Aug; 572(1-3):299-306. PubMed ID: 15304366
[TBL] [Abstract][Full Text] [Related]
17. Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA.
Stanker LH; Merrill P; Scotcher MC; Cheng LW
J Immunol Methods; 2008 Jul; 336(1):1-8. PubMed ID: 18452945
[TBL] [Abstract][Full Text] [Related]
18. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin.
Rummel A; Mahrhold S; Bigalke H; Binz T
FEBS J; 2011 Dec; 278(23):4506-15. PubMed ID: 21624052
[TBL] [Abstract][Full Text] [Related]
19. Effects of purification on the bioavailability of botulinum neurotoxin type A.
Cheng LW; Onisko B; Johnson EA; Reader JR; Griffey SM; Larson AE; Tepp WH; Stanker LH; Brandon DL; Carter JM
Toxicology; 2008 Jul; 249(2-3):123-9. PubMed ID: 18538461
[TBL] [Abstract][Full Text] [Related]
20. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.
Potter KJ; Bevins MA; Vassilieva EV; Chiruvolu VR; Smith T; Smith LA; Meagher MM
Protein Expr Purif; 1998 Aug; 13(3):357-65. PubMed ID: 9693060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
